The experimental drug neflamapimod reduced a key biomarker of neurodegeneration, which correlated with a slowing of cognitive ...

Neflamapimod is an oral p38 alpha kinase inhibitor that targets dysfunction and degeneration of acetylcholine-producing ...

Significant reduction in key neurodegeneration biomarker correlated with treatment response, suggesting neflamapimod may act on underlying disease CervoMed preparing to initiate Phase 3 registrational ...

Scheduled for Second Half of January -PURCHASE, N.Y., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing ...

Data demonstrates neflamapimod treatment led to significant reductions in plasma glial fibrillary acidic protein ( GFAP), a key marker of neuroinflammation-associated neurodegeneration, and increased ...

Alzheimer’s disease is the most commonly diagnosed form of dementia, but it’s far from the only one. In fact, most people who ...

Dementia is a highly prevalent condition, affecting 57 million people worldwide, with nearly 10 million new cases each year, ...

During certain times of the day, some people with dementia may become more confused and disoriented. Referred to by ...

Our memory reflects our brain health and it is often lost in old age, majorly due to dementia.Dementia is basically caused by ...

Evidence increasingly shows that chronic exposure to PM2.5, a neurotoxin, not only damages lungs and hearts but is also ...

There is increasing evidence that chronic exposure to PM2.5, a neurotoxin, not only damages lungs and hearts but is also ...

Patients with MCI, regardless of subtype, have a higher risk of developing hypertension, diabetes, and hyperlipidemia than cognitively normal individuals.